|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Advances in diagnosis,treatment and palliation of cholangiocarcinoma:1990-2009显示文摘Several advances in diagnosis,treatment and palliation of cholangiocarcinoma(CC)have occurred in the last decades.A multidisciplinary approach to this disease is therefore recommended.CC is a relatively rare tumor and the main risk factors are:chronic inflammation, genetic predisposition and congenital abnormalities of the biliary tree.While the incidence of intra-hepatic CC is increasing,the incidence of extra-hepatic CC is trending down.The only curative treatment for CC is surgical resection with negative margins.Liver transplantation has been proposed only for selected patients with hilar CC that cannot be resected who have no metastatic disease after a period of neoadjuvant chemo-radiation therapy.Magnetic resonance imaging/magnetic resonance cholangiopancreatography,positron emission tomography scan,endoscopic ultrasound and computed tomography scans are the most frequently used modalities for diagnosis and tumor staging.Adjuvant therapy,palliative chemotherapy and radiotherapy have been relatively ineffective for inoperable CC.For most of these patients biliary stenting provides effective palliation.Photodynamic therapy is an emerging palliative treatment that seems to provide pain relief,improve biliary patency and increase survival. The clinical utility of other emerging therapies such as transarterial chemoembolization,hepatic arterial chemoinfusion and high intensity intraductal ultrasound needs further study. | Murad Aljiffry Mark J Walsh Michele Molinari | 2009 | World Journal of Gastroenterology2009，15，34： | 82 |
| 2 | Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010显示文摘Several advances in genetics, diagnosis and palliation of pancreatic cancer (PC) have occurred in the last decades. A multidisciplinary approach to this disease is therefore recommended. PC is relatively common as it is the fourth leading cause of cancer related mortality. Most patients present with obstructive jaundice, epigastric or back pain, weight loss and anorexia. Despite improvements in diagnostic modalities, the majority of cases are still detected in advanced stages. The only curative treatment for PC remains surgical resection. No more than 20% of patients are candidates for surgery at the time of diagnosis and survival remains quite poor as adjuvant therapies are not very effective. A small percentage of patients with borderline non-resectable PC might benefit from neo-adjuvant chemoradiation therapy enabling them to undergo resection; however, randomized controlled studies are needed to prove the benefits of this strategy. Patients with unresectable PC benefit from palliative interventions such as biliary decompression and celiac plexus block. Further clinical trials to evaluate new chemo and radiation protocols as well as identification of genetic markers for PC are needed to improve the overall survival of patients affected by PC, as the current overall 5-year survival rate of patients affected by PC is still less than 5%. The aim of this article is to review the most recent high quality literature on this topic. | Chakshu Sharma Karim M Eltawil Paul D Renfrew Mark J Walsh Michele Molinari | 2011 | World Journal of Gastroenterology2011，17，7： | 28 |
| 3 | Chronic Obstructive Pulmonary Disease:Evidence for an Autoimmune Component显示文摘Chronic obstructive pulmonary disease (COPD) is characterized by an irreversible limitation on pulmonary airflow associated with chronic inflammation and mucous hypersecretion (chronic bronchitis) and/or the pathological destruction of alveolar airspaces leading to emphysema. COPD, predominantly as a result of tobacco smoke exposure, represents the fourth leading cause of mortality worldwide and its prevalence is increasing. Despite this, much of the basic mechanisms which contribute to disease progression remain to be elucidated and current therapeutic approaches are, for the most part, based upon alleviating patient symptoms (bronchodilators) as opposed to treating the underlying pathological mechanisms triggered in response to cigarette smoke exposure. The classic disease paradigm suggests that an imbalance of pulmonary matrix proteases versus anti-proteases underlies the tissue destruction and inflammation associated with COPD. However, there is a growing appreciation of the complex and multifaceted nature of the pathological mechanisms associated with disease progression. Recently, there has been mounting evidence indicating that COPD patients exhibit many of the characteristics of a classical autoimmune response. We will discuss current evidence in support of this paradigm and outline how future therapeutic approaches may be tailored to address this. | Anna M. Stefanska Patrick T. Walsh | 2009 | Cellular & Molecular Immunology2009，6，2： | 24 |
| 4 | 微创牙科学:文献回顾与最新进展(英文)显示文摘微创牙科学是指采用生物学方法而不是传统的牙体手术处理龋病,以最大限度地减少对牙体结构的破坏。这种新的龋病处理方法,将过去强调的视龋损为“洞”而反复充填的理念,转变为视龋损为口腔生态失衡而促使生物膜产生生物学变化。微创牙科学的目的在于阻止龋病进程,然后修复缺失的牙体结构和功能,最大限度地发挥牙体的愈合潜能。微创牙科学的处理方法可概括为3个步骤:(1)判定患者的患龋风险;(2)再矿化,即防止龋损形成并逆转未形成“洞”的浅龋;(3)修复,即控制龋活性,使愈合潜能最大化并修复龋损。龋病并非仅仅是牙体脱矿,而是一个因生物膜与牙界面生态和化学平衡失衡而致的反复的脱矿过程(生态菌斑学说)。饮食和生活方式(尤其是碳水化合物的摄入频次)、饮水、吸烟是导致生物膜生态和致病性的重要因素。椅旁评价菌斑和唾液的方法的问世,使得龋病危险评估和监测患者的顺从性成为可能。唾液的再矿化特性,可以通过使用能够释放Ca2+、P5+、F1-的再矿化剂(CPP-ACPandCPP-ACFP)而予强化。使用某些化学制剂(氟、氯已定和木糖醇),可改变菌斑的致病性。采用微创治疗方案,可修复早期龋损,增进患者的理解力和顺从性。本文从3个方面,详细论述了微创牙科学的概念、理论基础和操作方法。 | Andrew M. Brostek Andrew J. Bochenek Laurence J. Walsh | 2006 | 上海口腔医学2006，15，3： | 12 |
| 5 | 利用常间回文重复序列丛集介导的基因编辑评估Tet2和甲基转移酶3a在克隆性造血和心血管病中的作用显示文摘克隆性血细胞生成与死亡率、心血管病发生率增加有关。这种情况可能是由于造血干/祖细胞(hematopoietic stem/progenitor cells,HSPC)内的前白血病驱动基因的体细胞突变引起的。大约有40个候选驱动基因已被确定出来,但有研究证明在这些基因中,仅一个基因[10-11易位-2(TET2)]的突变在大鼠模型中可导致心血管病。 | Sano S Ohshima K Wang Y Katanasaka Y Sano M Walsh K 刘青 叶鹏 | 2018 | 中华高血压杂志2018，26，7： | 11 |
| 6 | Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases显示文摘Polycystic liver diseases(PLD)represent a group of genetic disorders in which cysts occur in the liver(autosomal dominant polycystic liver disease)or in combination with cysts in the kidneys(autosomal dominant polycystic kidney disease).Regardless of the genetic mutations,the natural history of these disorders is alike.The natural history of PLD is characterized by a continuous increase in the volume and the number of cysts.Both genders are affected;however,women have a higher prevalence.Most patients with PLD are asymptomatic and can be managed conservatively.Severe symptoms can affect 20%of patients who develop massive hepatomegaly with compression of the surrounding organs.Rrarely,patients with PLD suffer from acutecomplications caused by the torsion of hepatic cysts,intraluminal cystic hemorrhage and infections.The most common methods for the diagnosis of PLD are cross sectional imaging studies.Abdominal ultrasound and computerized tomography are the two most frequently used investigations.Magnetic resonance imaging is more sensitive and specific,and it is a valuable test for patients with intravenous contrast allergies or renal dysfunction.Different treatment modalities are available to physicians caring for these patients.Medical treatment has been ineffective.Percutaneous sclerotherapy,transarterial embolization,cyst fenestration,hepatic resection and liver transplantation are indicated to specific groups of patients and have to be tailored according to the extent of disease.This review outlines the current knowledge of the pathophysiology,clinical course,diagnosis and treatment strategies of PLD. | Bassam Abu-Wasel Caolan Walsh Valerie Keough Michele Molinari | 2013 | World Journal of Gastroenterology2013，19，35： | 10 |
| 7 | 澳大利亚临床共识指南:儿童卒中的诊断和急性期处理显示文摘卒中是导致儿童死亡的十大原因之一,幸存的致残患儿将面临几十年的残疾生活,给患儿及其家庭带来了巨大负担。由于安全性和有效性的证据有限,以及诊断的延误,目前卒中患儿无法接受再灌注治疗。儿童卒中诊断和急性期处理的澳大利亚临床共识指南,旨在最大限度地减少临床诊疗中的不确定性,并记录与成人卒中不同的危险因素、病因和假性卒中情况的最佳证据。临床问题的阐述来自于对2007年至2017年数据库的系统检索,但仅限于英语和儿科研究。该指南应用SIGN方法和国家健康与医学研究委员会系统对证据进行筛选和分类,通过推荐、评估、发展和评价系统(GRADE系统)对推荐进行强弱分级。该指南提供了60多项基于证据的推荐,以帮助参与院前和急症处理的临床医师快速识别儿童卒中,选择最合适的初步检查方案来确定诊断、明确病因,并选择最恰当的干预措施以挽救脑组织、预防复发。同时,指南也提供了颅内压和先天性心脏病管理方面的推荐。该指南的实施需要将院前和急诊系统重组,包括建立区域性卒中网络,建立儿科卒中疾病编码,快速MRI,以及对能够提供再灌注治疗的初级儿科卒中中心进行认证。该指南能够审核治疗的基准时间线,获得急性期的干预措施及预后判断。它还将促进澳大利亚儿童卒中登记的发展,并与国际登记处建立数据联系,以便准确收集卒中发病率、治疗和结果相关的数据。 | Medley TL Miteff C Andrews I Ware T Cheung M Monagle P Mandelstam S Wray A Pridmore C Troedson C Dale RC Fahey M Sinclair A Walsh P Stojanovski S Macka MT 徐佳丽(译) 吴川杰(译) 肖潇(译) 吕俊萱(译) 张博维(译) 吉训明(译) | 2019 | 中国脑血管病杂志2019，16，4： | 9 |
| 8 | 后顶叶空间注意功能的跨颅骨磁刺激仪研究显示文摘目的 探讨后顶叶的空间注意功能。方法 使用跨颅骨磁刺激仪 (TMS)干扰后顶叶的活动 ,观察被试在Conjunc tion作业中反应时间的变化。结果 使用TMS干扰后顶叶的活动时 ,初试的被试反应时间明显增加 ,但是非初试被试的反应时间没有变化。结论 后顶叶的作用不是记忆 。 | 王福顺 冯鉴强 Vincent Walsh | 2002 | 中国行为医学科学2002，11，1： | 9 |
| 9 | Definition and classification of cancer cachexia: an international consensus显示文摘 | Kenneth Fearon Florian Strasser Stefan D Anker Ingvar Bosaeus Eduardo Bruera Robin L Fainsinger Aminah Jatoi Charles Loprinzi Neil MacDonald Giovanni Mantovani Mellar Davis Maurizio Muscaritoli Faith Ottery Lukas Radbruch Paula Ravasco Declan Walsh Andrew | 2011 | Lancet Oncology2011，，5： | 8 |
| 10 | Electronic word-of-mouth via consumer-opinion platforms: What motivates consumers to articulate themselves on the Internet?显示文摘 | Thorsten Hennig-Thurau Kevin P. Gwinner Gianfranco Walsh Dwayne D. Gremler | 2004 | Journal of Interactive Marketing2004，，1： | 8 |
| 11 | 钠-葡萄糖共转运蛋白-2抑制剂或胰高血糖素样肽-1受体激动剂治疗成人2型糖尿病:临床实践指南显示文摘临床问题对于存在不同心血管风险及肾脏结局的2型糖尿病患者,在原有生活方式干预和/或其他降糖药物的基础上加用钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂和胰高血糖素样肽1(GLP-1)受体激动剂的获益及风险是什么?现行做法几十年来,2型糖尿病的治疗决策都以控制血糖为主导。SGLT-2抑制剂和GLP-1受体激动剂在传统观念中常被用于二甲双胍治疗后血糖仍控制不佳的患者。目前这一现状已经发生了改变,这得益于多项临床研究结果。研究显示SGLT-2抑制剂和GLP-1受体激动剂拥有独立于药物降糖作用之外的对于动脉粥样硬化性心血管病(CVD)和慢性肾脏病(CKD)的获益。建议本指南阐述了针对不同风险分层的成人2型糖尿病患者使用SGLT-2抑制剂或GLP-1受体激动剂的建议。•伴有3种或更少的心血管风险因素且不存在CVD或CKD:不建议启动SGLT-2抑制剂或GLP-1受体激动剂治疗。(推荐等级:弱)•伴有3种以上心血管风险因素且不存在CVD或CKD:建议启动SGLT-2抑制剂治疗,不建议启动GLP-1受体激动剂治疗。(推荐等级:弱)•已经存在CVD或CKD:建议启动SGLT-2抑制剂治疗和GLP-1受体激动剂治疗。(推荐等级:弱)•已经存在CVD和CKD:建议启动SGLT-2抑制剂治疗(推荐等级:强)和GLP-1受体激动剂治疗。(推荐等级:弱)•对于那些想要进一步降低CVD和CKD结局风险的患者:推荐优先启用SGLT-2抑制剂治疗而非GLP-1受体激动剂治疗。(推荐等级:弱)这项指南是如何制订的一个由患者、临床医生和方法学家共同组成的国际小组提出了这些推荐意见。这些推荐意见基于可信度较高的指南的标准,并使用GRADE分级方法进行评估。该小组采用了息者个体化的观点。证据一项关于获益与风险的系统综述和网络meta分析(764项随机对照研究,包括421346例参与者)发现SGLT-2抑制剂和GLP-1受体激动剂可以降低总体死亡率、心肌梗死发生率、终末期肾病或肾衰竭的发生率(中等至高等质量的证据)。在不同的亚组中这些药物对卒中、因心力衰竭所致住院和其他主要不良事件有不同的影响。药物绝对获益的程度因患者个体风险的不同有很大的差异。(例如,对于接受了超过5年药物治疗的1000例患者,在最低风险人群中死亡人数减少了5人,在最高风险人群中死亡人数减少了48人)。一项关于预后的综述确认了14种风险预测模型,其中一种(RECODe)在证据总结中报告了大部分基线风险评估数据,小组利用该模型以支持风险分层的建议。考虑到患者的价值观及个体差异,指南推荐的支撑证据包括一项对已发表论文的系统综述、一项患者焦点小组研究、一项临床问题总结,以及一项指南调查。指南解读我们依据不同的CVD和CKD风险水平,综合考虑获益、风险和其他因素的平衡,以及每一个风险组别的实际问题,来对推荐意见进行分层。本指南强烈建议CVD和CKD患者使用SGLT-2抑制剂治疗,这说明专家组认为其具有显著的获益。而对于其他成人2型糖尿病患者,推荐等级较弱,这说明专家组想要在获益、风险及治疗花费上取得一个更好的平衡。临床医生通过该指南可以使用可靠的风险计算模型,如RECODe,来明确其患者的个体心血管和肾脏疾病风险。医患交互式总结临床证据和制订决策有助于患者知晓治疗选择,包括进行共同决策。2型糖尿病人群(全球患病率不断增长1-2)正面临着不断增加的心血管疾病、肾脏病和其他并发症的风险3。数十年来,2型糖尿病的管理始终以控制血糖及糖化血红蛋白(HbA1c)为治疗目标4-5,但是,最近的高质量随机对照研究已经对这种以血糖为中心的治疗模式发起了挑战。研究结果显示,强化血糖控制未必会降低大血管不良事件,它还可能带来不利影响监管机构现在要求新型糖尿病药物必须证明其具有心血管和肾脏获益才能获得批准。对两类新药--钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂和胰高血糖素样肽1(GLP-1)受体激动剂(见框图1)的临床试验结果显示,在现有治疗方案(常规治疗)之上加用这些药物,对死亡、心肌梗死、卒中、心力衰竭和肾脏的结局(如进展为终末期肾病)都有获益8-12。 | Sheyu Li Per Olav Vandvik Lyubov Lytvyn Gordon H Guyatt Suetonia C Palmer Rene Rodriguez-Gutierrez Farid Foroutan Thomas Agoritsas Reed A C Siemieniuk Michael Walsh Lawrie Frere David J Tunnicliffe Evi V Nagler Veena Manja Bjφrn Olav Asvold Vivekanand Jha Mieke Vermandere Karim Gariani Qian Zhao Yan Ren Emma Jane Cartwright Patrick Gee Alan Wickes Linda Fems Robin Wright Ling Li Qiukui Hao Reem A Mustafa 无 郭鹤鸣(译) | 2021 | 英国医学杂志中文版2021，24，9： | 7 |
| 12 | Driver mutations of cancer epigenomes显示文摘Epigenetic 改变与癌症的所有方面被联系,从肿瘤开始到癌症前进和转移。DNA methylation 以及改变的染色质组织的损失和获得显著地作出贡献到联系癌症的显型,这现在很好被理解。更最近,新定序技术在 epigenetic 管理者允许司机变化的鉴定,提供在癌症 epigenome 和基因改变之间的一个机械学的连接。激活变化的 Oncogenic 现在被知道发生在很多个 epigenetic 修饰词(即 IDH1/2, EZH2, DNMT3A ) ,指出涉及 tumorigenesis 的 epigenetic 小径。同样,调查进在染色质修饰词使变化失去活性的角色(即 KDM6A, CREBBP/EP300, SMARCB1 ) 含有许多这些基因作为肿瘤 suppressors。有趣地,很多个瘤被变化的过多在 epigenetic 管理者定义,包括肾,膀胱,和 adenoid 膀胱的癌。特别地罢工是在小儿科的 glioma 的经常的 histone H3.3 变化的发现,长糟糕留下了的一个特别地好攻击的瘤理解。癌症 epigenetics 是有为改进癌症结果的许多潜力的相对新的、有希望的边疆。已经,象 5-azacytidine 和 decitabine 那样的治疗证明了在癌症指向 epigenetic 改变能导致有形的好处。理解基因改变怎么产生癌症 epigenome 将为开发更好预示、治疗学的策略提供新可能性。 | David M. Roy Logan A. Walsh Timothy A. Chan | 2014 | Protein & Cell2014，5，4： | 7 |
| 13 | MicroRNA sequences modulating inflammation and lipid accumulation in macrophage “foam” cells: Implications for atherosclerosis显示文摘Accumulation of macrophage'foam'cells,laden with cholesterol and cholesteryl ester,within the intima of large arteries,is a hallmark of early'fatty streak'lesions which can progress to complex,multicellular atheromatous plaques,involving lipoproteins from the bloodstream and cells of the innate and adaptive immune response.Sterol accumulation triggers induction of genes encoding proteins mediating the atheroprotective cholesterol efflux pathway.Within the arterial intima,however,this mechanism is overwhelmed,leading to distinct changes in macrophage phenotype and inflammatory status.Over the last decade marked gains have been made in understanding of the epigenetic landscape which influence macrophage function,and in particular the importance of small non-coding micro-RNA(miRNA)sequences in this context.This review identifies some of the miRNA sequences which play a key role in regulating'foam'cell formation and atherogenesis,highlighting sequences involved in cholesterol accumulation,those influencing inflammation in sterol-loaded cells,and novel sequences and pathways which may offer new strategies to influence macrophage function within atherosclerotic lesions. | Richard James Lightbody Janice Marie Walsh Taylor Yvonne Dempsie Annette Graham | 2020 | World Journal of Cardiology2020，12，7： | 7 |
| 14 | Paediatric cholestatic liver disease:Diagnosis,assessment of disease progression and mechanisms of fibrogenesis显示文摘Cholestatic liver disease causes significant morbidity and mortality in children.The diagnosis and management of these diseases can be complicated by an inability to detect early stages of fibrosis and a lack of adequate interventional therapy.There is no single gold standard test that accurately reflects the presence of liver disease,or that can be used to monitor fibrosis progression,particularly in conditions such as cystic fibrosis.This has lead to controversy over how suspected liver disease in children is detected and diagnosed.This review discusses the challenges in using commonly available methods to diagnose hepatic fibrosis and monitor disease progression in children with cholestatic liver disease.In addition,the review examines the mechanisms hypothesised to be involved in the development of hepatic fibrogenesis in paediatric cholestatic liver injury which may ultimately aid in identifying new modalities to assist in both disease detection and therapeutic intervention. | Tamara N Pereira Meagan J Walsh Peter J Lewindon Grant A Ramm | 2010 | World Journal of Gastrointestinal Pathophysiology2010，1，2： | 7 |
| 15 | 男性不育的手术技术显示文摘男性不育的评估和手术治疗领域经过数次演变和扩展后,目前已经有了更精确的诊断和适应个人的治疗方法,死亡率逐渐降低,成功率逐渐提高.男性不育手术目前被分为四个主要的大类:1)诊断手术;2)改善精子生成的手术;3)提高精子运输的手术;4)提取精子用于IVF—ICSI的手术.尽管现在的男性不育治疗效果比以前有了显著的提高,但还是有些达不到妊娠的要求,这可能是由一些我们还不知道的因素造成的。医生在治疗不育时应提倡“夫妻双方共同治疗”的准则,要求在实施具体的治疗方案之前,夫妻双方都进行彻底的评估,并进行广泛讨论决定方案。 | Natalya A Lopushnyan Thomas J Walsh | 2012 | Asian Journal of Andrology2012，14，1： | 7 |
| 16 | 柴油机排放控制的全球趋势——1997年最新评述显示文摘世界许多地区轻型柴油车的销售有明显增长的趋势,部分原因是全球对温室效应关切的驱动。这种趋势对全球环境将产生许多积极的影响,其中包括降低燃油耗,从而降低CO_2排放量、CO和HC排放量(特别是在冷起动条件时)以及大大降低碳氢化合物的挥发。然而,由于较高的NO_x和颗粒排放,柴油机销售增长具有下降的趋势。这些污染物继续受到世界大多数地区的高度关注。因此,世界各国的柴油机排放法规越来越严格,推动了降低排放的技术不断发展。发动机和燃烧的改进明显降低了现代发动机的NO_x和颗粒排放。然而有人提出这样的问题,关于颗粒排放量究竟是真正降低了,还是仅仅改变到一个较小的尺寸范围内。本文将对降低柴油机NO_x和颗粒排放的规范状况加以评论和总结。 | Walsh M P 王耀清 | 1998 | 国外内燃机1998，30，5： | 6 |
| 17 | Cu_2ZnSnS_4类四元硫族半导体的理论研究--以二元、三元、四元半导体的演化为思路显示文摘在过去60多年中,人们对半导体的研究集中在一元、二元和三元半导体方面,最近,出于寻找新型廉价、环保、高效光伏转换材料的需要,Cu2ZnSnS4类Ⅰ2-Ⅱ-Ⅳ- Ⅵ4型四元硫族半导体吸引了人们越来越多的关注,它在光催化和热电等多方面的应用也不断被发掘.然而,对于这类四元半导体的基本性质,如晶体结构和电子结构,人们知之甚少,很多研究还停留在经验阶段.文章首先简要回顾了这类半导体的由来和在应用方面的最新进展,然后详细介绍了文章作者对这类四元半导体的第一性原理计算研究工作的进展,其中包括:系统研究了这类硫族半导体在从二元向三元再向四元的演化过程中晶体结构和电子能带结构变化的规律,总结了元素成分对其影响的一般趋势,并结合实验结果分析了这类四元半导体晶格结构表征和带隙测量中易于出现的混淆;文章作者还以Cu2ZnSnS4为例,考察了这类四元化合物相对二元、三元化合物的相稳定性和本征缺陷性质.文章介绍的研究结果将为一系列Ⅰ2-Ⅱ-Ⅳ- Ⅵ4型四元半导体的深入研究提供基础. | 陈时友 龚新高 Aron Walsh 魏苏淮 | 2011 | 物理2011，40，4： | 6 |
| 18 | PM2.5: global progress in controlling the motor vehicle contribution显示文摘 | Michael Patrick WALSH | 2014 | Frontiers of Environmental Science & Engineering2014，8，1： | 6 |
| 19 | 《牙科修复学》显示文摘《牙科修复学》一书内容丰富、系统全面、资料新颖、图文并茂,基本涵盖了牙科修复学的各个方面,从口腔诊疗计划的制订到牙体、牙列缺损的修复,系统地介绍了牙科修复学最新的、综合性的理论、 | A. Damien Walmsley(原著) Trevor F. Walsh(原著) F. J. Trevor Burke(原著) 陈吉华(主译) | 2006 | 实用口腔医学杂志2006，22，2： | 5 |
| 20 | Gastroenterologist perceptions of faecal microbiota transplantation显示文摘AIM: To explore gastroenterologist perceptions towards and experience with faecal microbiota transplantation(FMT).METHODS: A questionnaire survey consisting of 17 questions was created to assess gastroenterologists' attitude towards and experience with FMT. This was anonymously distributed in hard copy format amongst attendees at gastroenterology meetings in Australia between October 2013 and April 2014. Basic descriptive statistical analyses were performed.RESULTS: Fifty-two clinicians participated. Twenty one percent had previously referred patients for FMT,8% more than once. Ninety percent would refer patients with Clostridium difficile infection(CDI) for FMT if easily available,37% for ulcerative colitis,13% for Crohn's disease and 6% for irritable bowel syndrome. Six percent would not refer any indication,including recurrent CDI. Eighty-six percent would enroll patients in FMT clinical trials. Thirty-seven percent considered the optimal mode of FMT administration transcolonoscopic,17% nasoduodenal,13% enema and 8% oral capsule. The greatest concerns regarding FMT were: 42% lack of evidence,12% infection risk,10% non infectious adverse effects/lack of safety data,10% aesthetic,10% lack of efficacy,4% disease exacerbation,and 2% inappropriate use; 6% had no concerns. Seventy seven percent believed there is a lack of accessibility while 52% had an interest in learning how to provide FMT. Only 6% offered FMT at their institution.CONCLUSION: Despite general enthusiasm,most gastroenterologists have limited experience with,or access to,FMT. The greatest concerns were lack of supportive evidence and safety issues. However a significant proportion would refer indications other than CDI for FMT despite insufficient evidence. These data provide guidance on where education and training are required. | Sudarshan Paramsothy Alissa J Walsh Thomas Borody Douglas Samuel Johan van den Bogaerde Rupert WL Leong Susan Connor Watson Ng Hazel M Mitchell Nadeem O Kaakoush Michael A Kamm | 2015 | World Journal of Gastroenterology2015，21，38： | 5 |
您所在的机构暂未开通此部分的功能，请联系管理员